Lyell is an immuno-oncology company dedicated to reprogramming T cells to achieve curative therapies for solid tumors. The company takes a deliberate approach to solving what it believes to be the major barriers to successful adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is combining its proprietary ex vivo genetic and epigenetic reprogramming technologies that address these barriers with T cell receptors (TCRs), tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptors (CARs). 

Biotechnology

Therapeutics

Lyell Immunopharma

Lyell Immunopharma's headquarters in South San Francisco, CA, United States

Lynn Seely

David Shook

Stasiu Nowak

Julie Urvater

Wen Liu

Ellen Rose

Charles Newton

Tina Albertson

Gary Lee

Stephen Hill

Catherine Friedman

Robert Nelsen

William Rieflin

Otis Brawley

Hans Bishop

Rick Klausner

Elizabeth Nabel

Crystal Mackall

Stan Riddell

Description

People (25)

Gary Lee

Bryan Selby

Ann Tomlin

Ellen Rose

Dylan Lewis Cfa, Cpa, Ca

Shobha Potluri

Benjamin H.

Jia Lu

Ken Xiong

Rachel Lynn

Jessica Barragan

Christina Cheung

Jessica Fioravanti Dvm

Lora Zhao

Neeraj S.

Riley Allen

Chi-Mei Cheng

Edison H.

Linda Liu

Julie Jeffery

Wen Liu

Eric Hoffmann

Chris Michon

James Cregg

Ajath S.

Jobs